Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|12|23|2663-2681

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.12, Iss.23, 2005-11, pp. : 2663-2681

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects

By  

Current Medicinal Chemistry, Vol. 11, Iss. 16, 2004-08 ,pp. : 2161-2183

Bentham Science Publishers

Access to resources Recommend Favorite

ICL 670: effective oral iron chelation therapy

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670

By  

Current Medicinal Chemistry, Vol. 10, Iss. 12, 2003-06 ,pp. : 1065-1076

Bentham Science Publishers

Access to resources Recommend Favorite

Hydroxypyridone iron chelators, L1 and analogues. An 17 O NMR study

By Cerioni G.   Plumitallo A.   Batzella M.G.   Locci F.  

European Journal of Medicinal Chemistry, Vol. 34, Iss. 9, 1999-09 ,pp. : 759-763

Elsevier

Access to resources Recommend Favorite

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD   Taher A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite